Ixazomib should be taken under the guidance of a professional physician and should not be taken without medical supervision.
Ixazomib Usage Guidelines
1. Indications and Usage
Ixazomib in combination with lenalidomide and dexamethasone is indicated for patients with multiple myeloma who have received at least one prior therapy. It is not recommended for maintenance therapy or newly diagnosed patients (unless in a clinical trial).
2. Dosage Regimen
(1) Recommended starting dose: 4 mg orally once daily on days 1, 8, and 15 of a 28-day treatment cycle.
(2) Combination therapy: Lenalidomide (days 1–21, 25 mg/day) and dexamethasone (days 1, 8, 15, and 22, 40 mg/day).
(3) Timing of administration: Should be taken at least 1 hour before a meal or at least 2 hours after a meal, swallowed whole, without chewing or opening.
3. Management of Missed Doses or Vomiting
If a dose is missed, take it only if the next dose is ≥72 hours later. If vomiting occurs after taking the medication, no additional dose is needed; take the next dose as scheduled.
Ixazomib Dosage Adjustment
1. Adjustments Based on Adverse Reactions
(1) Thrombocytopenia (<30,000/mm³): Discontinue ixazomib and lenalidomide, and reduce the dose sequentially upon recovery.
(2) Neutropenia (<500/mm³): Discontinue the medication, consider G-CSF support, and reduce the dose upon recovery.
(3) Rash (Grade 2-3): Discontinue lenalidomide, and alternately reduce the dose of ixazomib upon recurrence.
(4) Peripheral neuropathy (Grade 2 with pain or Grade 3): Discontinue ixazomib, and reduce the dose upon recovery; discontinue if Grade 4.
(5) Other non-hematologic toxicities (Grade 3-4): Discontinue and reduce the dose upon recovery.
2. Starting Dose for Patients with Hepatic or Renal Impairment
Moderate or severe hepatic impairment (total bilirubin >1.5×ULN): Starting dose reduced to 3 mg.
Severe renal impairment or end-stage renal disease requiring dialysis (CrCl <30 mL/min): Starting dose reduced to 3 mg, regardless of dialysis time.
Special Populations for Ixazomib Use
1. Pregnancy and Lactation
(1) Pregnancy: Ixazomib has embryo-fetal toxicity. Men and women of reproductive age should use effective non-hormonal contraception during treatment and for 90 days after the last dose.
(2) Lactation: Breastfeeding is prohibited during treatment and for 90 days after discontinuation.
2. Elderly Patients
In clinical studies, approximately 55% of patients were ≥65 years old. No differences in safety or efficacy were found, but individualized assessment is still necessary.
3. Hepatic or Renal Impairment
(1) Patients with hepatic impairment: The dose should be reduced to 3 mg for moderate to severe cases.
(2) Patients with kidney damage: Severe patients or those on dialysis should also start with 3 mg. Ixazomib cannot be removed by dialysis.
